Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn's disease from intestinal lymphoma, intestinal tuberculosis and Behcet's syndrome

American Journal of the Medical Sciences

Volumn 346, Issue 6, 2013, Pages 467-472

  Liu, Song ^a,d   Ren, Jianan ^a   Xia, Qiuyuan ^b   Wu, Xiuwen ^a   Han, Gang ^c   Ren, Huajian ^a   Yan, Dongsheng ^a   Wang, Gefei ^a   Gu, Guosheng ^a   Li, Jieshou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Biomarker; Crohn's disease; CRP; Differentiation; ESR

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BEHCET DISEASE; BLOOD SAMPLING; BODY MASS; CASE CONTROL STUDY; CELL DIFFERENTIATION; CLINICAL EVALUATION; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENDER; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE LYMPHOMA; INTESTINE TUBERCULOSIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PATHOLOGY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE;

EID: 84890856624     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182959a18     Document Type: Article

References (30)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet 2007;369:1641-57
2. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis 2011;17:471-8
3. Zhou ZY, Luo HS. Differential diagnosis between Crohn's disease and intestinal tuberculosis in China. Int J Clin Pract 2006;60:212-4
4. Jung YS, Cheon JH, Park SJ, et al. Long-term clinical outcomes of Crohn's disease and intestinal Behcet's disease. Inflamm Bowel Dis 2013; 19:99-105
5. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817-26 e2
6. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: Current practices and recent advances. Transl Res 2012;159:313-25
7. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16:112-24
8. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet 1990;335:1078-80
9. Mendes D, Correia M, Barbedo M, et al. Behcet's disease - a contemporary review. J Autoimmun 2009;32:178-88
10. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 2006;55:749-53
11. Sutherland AD, Gearry RB, Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008;51:1283-91
12. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-24
13. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007;56:1394-403
14. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822-9
15. Sipponen T, Savilahti E, Kolho KL, et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-6
16. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002;97:1458-62
17. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:123-8
18. Darlington GJ, Wilson DR, Lachman LB. Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro. J Cell Biol 1986; 103:787-93
19. Siegmund B. Mesenteric fat in Crohn's disease: The hot spot of inflammation? Gut 2012;61:3-5
20. Peyrin-Biroulet L, Gonzalez F, Dubuquoy L, et al. Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut 2012;61:78-85
21. Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002;14: 409-12
22. Shine B, Berghouse L, Jones JE, et al. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985;148:105-9
23. Beattie RM, Walker-Smith JA,Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995;73:354-5
24. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351-7
25. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805-12
26. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12:351-9
27. Cakal B, Akoz AG, Ustundag Y, et al. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig Dis Sci 2009; 54:842-7
28. Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007;52:2063-8
29. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: Useful, magic, or unnecessary toys? Gut 2006;55:426-31
30. Khan K, Schwarzenberg SJ, Sharp H, et al. Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm Bowel Dis 2002;8:325-9